Formulation Development
ProBioGen & ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen and ImmunOs Therapeutics recently announcd the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs’ lead program for the….
Kala Pharmaceuticals Receives FDA Fast Track Designation for Human MSC-S Therapy for Persistent Corneal Epithelial Defect
Kala Pharmaceuticals, Inc. recently announced the US FDA has granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of….
Biogen Exercises Option With Denali to Develop & Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
Biogen Inc. and Denali Therapeutics Inc. recently announced Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:Aβ). Accumulation of Aβ plaque in….
Dyadic Announces Expanded Licensing Agreement to Develop & Commercialize Vaccines & Biologics for African Continent
Dyadic International, Inc. recently announced it signed an expanded licensing agreement for its C1-cell protein expression platform with South Africa’s Rubic One Health to develop,…
Blue Water Vaccines Announces Signing of Sponsored Research Agreement With The University of Texas Health Science Center at San Antonio
Blue Water Vaccines Inc. recently announced the signing of a Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to…
Meridian Medical Technologies Investing $100+ Million in Bridgeton, MO, Expansion
Meridian Medical Technologies recently announced during National Community Development Week it will expand manufacturing capabilities in….
Paradigm Biopharmaceuticals Says Phase 2 Osteoarthritis Trial Shows Signs of Disease Modification
Paradigm Biopharmaceuticals Ltd recently announced analysis of 6-month trial data shows injectable pentosan polysulfate sodium (iPPS) may slow the progression of osteoarthritis of the knee.…
Centogene Extends Strategic Partnership With Takeda
Centogene N.V. recently announced it has extended its partnership with Takeda to diagnose patients with Lysosomal Storage Disorders (LSDs). Under the renewed 1-year partnership agreement,…
Eterna Therapeutics & Lincoln Park Capital Enter Common Stock Purchase Agreement for Up to $10 Million
Eterna Therapeutics Inc. recently announced it has entered into a common stock purchase agreement for up to $10 million with Lincoln Park Capital Fund, LLC.…
Pharmaceutical Contract Manufacturing Market is Expected to Reach $171.3 Billion
The Pharmaceutical Contract Manufacturing industry is expected to continue to grow in the near future due to a number of factors. The aging population is…
Celanese Announces Agreement With Glaukos Corporation for Sustained-Release Glaucoma Treatment
Celanese Corporation, a global specialty materials and chemical company, recently announced it has entered into an agreement with Glaukos Corporation to supply its VitalDose® Drug Delivery Platform for use as….
QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of Targeting Metastatic Bone Cancer
QSAM Biosciences Inc. recently announced the opening of enrollment into the second grouping of participants (Cohort 2) after completing Cohort 1 in February in its…
AI Therapeutics Announces Positive Results From Phase 2a Biomarker-Driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis
AI Therapeutics, Inc. recently announced positive results from a Phase 2a clinical trial of AIT-101 (LAM-002A) in patients with C9ORF72 amyotrophic lateral sclerosis (ALS). In…
Bora Pharmaceuticals & Celltrion Partner to Expand OSD Capabilities in APAC Market
Bora Pharmaceuticals Co., Ltd. and Celltrion Asia Pacific Pte., Ltd. recently announced their partnership to contract manufacture and commercialize a range of oral dosage form drugs (OSD) across the APAC region…..
RespireRx Pharmaceuticals Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders
RespireRx Pharmaceuticals Inc. recently announced entering into a material transfer agreement with University College London (UCL) as part of a collaborative research effort involving Dr.…
Lonza & ABL Bio Collaborate in the Development & Manufacture of Bispecific Antibody Product
Lonza recently announced it has an agreement with ABL Bio to support the development and manufacturing of ABL Bio’s new bispecific antibody product….
Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy
Zevra Therapeutics, Inc. recently announced the submission of an Investigational New Drug (IND) application seeking authorization from the US FDA to begin a Phase 1…
Caribou Biosciences Announces FDA Granted Fast Track Designation for Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Caribou Biosciences, Inc. recently announced the US FDA has granted Fast Track designation to CB-011, which is being developed for relapsed or refractory multiple myeloma…
Eckert & Ziegler to Supply POINT Biopharma With Actinium-225
Eckert & Ziegler (ISIN DE0005659700, TecDAX) and a subsidiary of POINT Biopharma Global Inc. have signed an agreement on the supply of Actinium-225 (non-carrier-added Ac-225).…
Absci Partners With Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology
Absci Corporation and M2GEN recently announced a partnership to create new cancer medicines and bring them to market at unprecedented speed. Absci’s generative AI drug creation platform will tap into M2GEN’s clinical and….
